|Referral date||01 October 2013|
Scoped as part of Batch 31
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|14 April 2014||
As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer in patients whose disease has not progressed after first line therapy .
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for pazopanib in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
For further information on our processes and methods, please see our CHTE processes and methods manual